Lombard Medical (EVAR) Misses Q2 EPS by 2c; Revises FY16 Revenue Outlook
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Lombard Medical (NASDAQ: EVAR) reported Q2 EPS of ($0.42), $0.02 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $3.8 million.
Due to the suspension of the US commercial operation, Lombard feels it is also prudent to amend its revenue guidance for the year to between $13 million and $15 million, driven in the second half by continued procedure and revenue growth in the Company’s go-forward core markets of Europe and Japan.
**** The Street sees FY16 revenue of $17.6 million.
For earnings history and earnings-related data on Lombard Medical (EVAR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Corelogic (CLGX) Tops Q3 EPS by 7c, Expects to Achieve Upper Ends of FY16 Guidance
- Crane Co. (CR) Tops Q3 EPS by 5c, Updates FY Guidance
- Buckeye Partners (BPL) Tops Q3 EPS by 22c
Create E-mail Alert Related CategoriesEarnings, Guidance, Hot Guidance
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!